Incretin and metabolic peptides studied for glycemic control and fat loss.
Metabolic peptides are among the most clinically validated classes in modern medicine. The incretin axis — GLP-1, GIP, and glucagon receptor signaling — coordinates insulin secretion, satiety, gastric emptying, and energy expenditure, and engineered agonists of these receptors now anchor the treatment of type 2 diabetes and obesity.
Research in this area spans single-, dual-, and triple-receptor agonists, amylin analogs, and adipose-selective fragments. Endpoints commonly studied include glycemic control, body-weight reduction, MASH/hepatic-fat resolution, and cardiovascular risk — with half-life extension (fatty-acid acylation, DPP-4 resistance) a recurring engineering theme.
Long-acting GLP-1 receptor agonist for glycemic control and weight management.
View profileDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
View profileInvestigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.
View profileLong-acting amylin analog studied alongside semaglutide as CagriSema.
View profileThe archetypal protein biologic — a 51-amino-acid two-chain hormone, disulfide-linked, and the first recombinant DNA drug ever marketed.
View profileInsulin’s counter-hormone — a 29-amino-acid peptide that raises blood glucose, the emergency rescue for severe lows, and the "G" in the new triple agonists.
View profileGHRH analog FDA-approved for HIV-associated lipodystrophy.
View profileAn anti-myostatin antibody (Regeneron) now studied in obesity combinations to cut lean-mass loss and deepen fat loss alongside semaglutide.
View profileA "sweeping" anti-myostatin antibody (Roche/Chugai) that not only blocks but actively clears myostatin — a cautionary case after its rare-disease trials failed.
View profileAn anti-activin-A antibody (Regeneron) — closest to approval of the axis (FOP), and a partner in obesity muscle-preservation combinations.
View profileAn antibody that blocks the activin type II receptor itself — shutting off myostatin AND activin signaling at once; famous for adding muscle while cutting fat.
View profileMitochondrially-encoded peptide with reported insulin-sensitizing activity.
View profileC-terminal hGH fragment (177–191) historically investigated for lipolysis.
View profileSmall-molecule NNMT inhibitor (often catalogued alongside peptides).
View profileThe most studied are incretin receptor agonists — GLP-1, dual GLP-1/GIP, and triple GLP-1/GIP/glucagon agonists — alongside amylin analogs. They act on satiety, insulin secretion, gastric emptying, and energy expenditure.
In studies they slow gastric emptying and signal satiety in the brain while improving glucose-dependent insulin release, which together reduce caloric intake and improve glycemic control.
Several GLP-1 and dual-agonist peptides are FDA-approved for type 2 diabetes and chronic weight management; others remain investigational. This page is a research reference, not medical advice.
How to weigh this evidence
Preclinical, observational, and randomized findings carry very different weight. The evidence hierarchy shows how to rank what you read before drawing conclusions.
Put the science to work — interactive utilities that run right here.
Ask in plain language — citation-backed answers from PubMed, PubChem & trials.
Build a peptide residue by residue with live chemistry, challenges & XP.
Sequence properties — pI, ε280, net charge & synthesis-difficulty flags.
Paste a certificate of analysis; grade its transparency and spot red flags.
Dose, dilution and syringe-unit math for reconstituting a vial.
Search PubChem for structures, molecular formulae and weights.
Which peptides are best studied for weight loss & metabolic health, how they compare, and what the clinical evidence shows — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.